

118TH CONGRESS
1ST SESSION

S. 476

To amend title XI of the Social Security Act to protect access to genetically targeted technologies.

IN THE SENATE OF THE UNITED STATES

FEBRUARY 16, 2023

Mr. MENENDEZ (for himself and Mrs. BLACKBURN) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To amend title XI of the Social Security Act to protect access to genetically targeted technologies.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Maintaining Invest-
5 ments in New Innovation Act”.

6 **SEC. 2. AMENDMENT TO DEFINITION OF QUALIFYING SIN-**

7 **GLE SOURCE DRUG.**

8 Section 1192(e) of the Social Security Act (42 U.S.C.
9 1320f–1(e)) is amended—

1 (1) in paragraph (1)(A)(ii), by inserting “(or,
2 in the case of an advanced drug product (as defined
3 in paragraph (4)), 11 years)” after “7 years”; and

4 (2) by adding at the end the following new
5 paragraph:

6 “(4) **ADVANCED DRUG PRODUCT DEFINED.**—
7 For purposes of paragraph (1)(A)(ii), the term ‘ad-
8 vanced drug product’ means a drug that incor-
9 porates or utilizes a genetically targeted technology
10 (as defined in section 529A(c)(2) of the Federal
11 Food, Drug, and Cosmetic Act) that may result in
12 the modulation (including suppression, up-regula-
13 tion, or activation) of the function of a gene or its
14 associated gene product.”.

○